Melphalan treatment to shrink eye melanoma before other therapy
Treatments studied
Part of Cancer, Eyes & vision, Skin clinical trials.
This early-phase study tests whether melphalan can be used to reduce (shrink) a type of eye cancer called choroidal melanoma before additional treatment. It may help by controlling tumor size while doctors closely monitor the eye and outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old
- You have a choroidal melanoma that measures at least 8 mm thick on ultrasound
- You can understand the study and sign the consent form
- Your pupils can be dilated for eye exams and you can cooperate with additional testing
- The melanoma must not be too wide (basal diameter 18 mm or less)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 study tests whether taking melatonin after treatment for uveal melanoma can reduce the chance that the cancer returns or spreads to other parts of the body. It is aimed at people with higher-risk eye melanoma features.
This trial tests immunotherapy before surgery for people with high-risk eye melanoma (uveal melanoma). You’ll get treatment to help your immune system fight the cancer, then have your eye removed. After surgery, you’ll be followed to see how well the treatment worked.
This trial tests a drug called darovasertib given before standard surgery for primary uveal melanoma (a type of eye cancer that hasn't spread). The goal is to see if the drug can shrink the tumor and improve outcomes.
This study tests how well the liver responds to a treatment called percutaneous hepatic perfusion with melphalan (chemotherapy delivered directly to the liver) in people with uveal melanoma that has spread to the liver. The goal is to see how the immune system reacts and if the treatment helps control the disease.
This trial tests a new drug, RBP-01, given before either surgery to remove the eye or radiation therapy, to see if it can help treat a type of eye cancer called uveal melanoma. It may offer a new option for people with larger tumors or those at risk of vision loss from standard treatment.
This study looks back at past medical records of people diagnosed with uveal melanoma. It helps researchers learn about the typical course of the disease by analyzing what already happened in care.
Hear when a new Uveal Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.